

ROI in Pharmaceutical R&D: How to Halt the Decline

<https://marketpublishers.com/r/RDA9019676C8EN.html>

Date: December 2019

Pages: 196

Price: US\$ 2,750.00 (Single User License)

ID: RDA9019676C8EN

Abstracts

REPORT SCOPE:

The scope of this study begins with the challenges facing biotech and pharmaceutical companies today. It goes on to discuss regulatory approval processes in various countries, how these are changing, and the knock-on effects which the pharma/biotech companies will have to address. The report then reviews several key financial ratios, then discusses how to maximize clinical development success rate. We then go into how machine learning (ML) and artificial intelligence (AI), along with Big Data, are disrupting the pharma/biotech industry, in a positive way. The report then reviews the global markets for treatments for selected cancers, chronic diseases, cardiovascular disease, neurological diseases, infectious diseases and rare diseases. Chapter 15 discusses how companies need to deeply integrate ML, AI and Big Data into drug discovery and clinical testing—or risk falling behind the competition. The report wraps up with summaries of selected companies active in these spaces and beginning to utilize digital tools in R&D.

REPORT INCLUDES:

49 data tables and 30 additional tables

An assessment of return on investment (ROI) in R&D by top pharmaceutical companies within the industry

Analyses of the global market trends for various chronic disease areas, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2024

Pipeline analysis of various therapeutic drugs with oncology being the largest,

and coverage of ongoing clinical trials and promising forthcoming therapies in late stage etc.

Outlining details of many factors involved in calculating ROI in R&D in pharma and how some of those factors are adjusted/developed to improve R&D ROI

Discussion of the competitive landscape and key mergers and acquisition deals, partnerships, collaborations during the timeframe, 2014-2024

Profile descriptions of top 15 pharmaceutical companies, their sales data, market capitalization and areas of R&D etc., including 23andMe, AstraZeneca PLC, Celgene Corp., Eli Lilly and Co., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc. and Sanofi

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY

ROI and R&D Outlays
Using Technology to Weed Out Losers, Focus on Potential Winners
Identifying Biomarkers
Revolutionizing Clinical Research with AI, ML and Patient Centricity
Global Oncology Markets by Region and Selected Types
Global Chronic Disease Drugs Market by Region
Global Cardiovascular Drugs Market by Region
Global Neurology Therapies Market by Region
Global Market for Infectious Disease Treatments by Region
Global Market for Orphan Drugs by Region
Wanted: Digitally Literate Employees Open to Continuous Learning

CHAPTER 3 CHALLENGES FACING PHARMA AND BIOTECH COMPANIES

Strong Revenues, but Decreasing ROI
Tracking the Decline in ROI
Reasons that IRR Has Been Exceptionally Low
The Competitive, Expensive Search for Novel Drugs
Eroom's Law
Emerging Global Players from India, China, Russia
Expiring Patents
Complying with Changing Regulatory Environments
Pricing Pressures in the US and Elsewhere
Traditional Structure is Blurring

Increasing Complexity of Clinical Trials
Oncology Clinical Trials Remain Complex
Is Oncology Research Showing the Way?
Patient Recruitment Consumes a Major Part of Trial Duration
Is the Pool of Viable New Drug Targets Diminishing?
The Malfunctioning Clinical Trial System
Solutions are Out There, and Already Working
The 21st Century Cures Act of 2016
The US FDA's New Population Pharmacokinetics Guidance Document
Pharma Market Update
M&A Activity
Biotech Market Update
Next-Generation Biotherapeutics Pipelines Have More than Doubled
Biotech Pricing Pressure
What's Ahead

CHAPTER 4 REGULATORY OVERVIEW AND NEW DRUG APPROVALS

Improving Regulatory Compliance
Drug Development Continues to be Slow Process
Record New Drug Approvals in 2018
US FDA Selected Drug Approvals
Drug Approval Processes in the US, EMA, China, Japan
US FDA and the EU's EMA
China's Drug Regulatory Process
Japan's Drug Regulatory Process

CHAPTER 5 KEY FINANCIAL RATIOS FOR PHARMA AND BIOTECH COMPANIES

Return on Investment and Project-wise ROI
Ensuring Financial Accountability for R&D Outlays
Return on Research Capital (RORC)
Profitability Ratios
Liquidity and Debt Coverage Ratios
Return on Equity (ROE)

CHAPTER 6 MAXIMIZING CLINICAL DEVELOPMENT SUCCESS RATES

Driving Change in Clinical Development

Utilizing Mobile Health Technologies

Ramping Up Real-World Data and Real-World Evidence: the FDA's New RWE Framework

Maximizing Immuno-Oncology Clinical Trial Success with Immune-Related Response Criteria (irRC)

irRC More Useful Than RECIST for immune-oncology drugs

Case Study: Ipilimumab

Identifying Biomarkers

Challenges and Hurdles to Biomarker Detection and Usage

Use of Patient-Reported Outcomes and Pools of Prescreened Patients

Predictive Analytics

Revolutionizing Clinical Research with AI, ML and Patient Centricity

One Example: Patient Centricity Enabled by the Medidata Patient Cloud

23andMe Wants to Solve the Patient Recruitment Problem

CHAPTER 7 THE ADVANTAGES OF BEING—OR ACTING—SMALL

Breaking Down the Silo Mentality

Just Say No

Turn on a Dime

Small Companies with Big Visions

Virgo Surgical Video Solutions

Ovid Therapeutics

Melinta Therapeutics

Applied Genetic Technologies

BioCryst Pharmaceuticals

CHAPTER 8 THE DIGITAL TRANSFORMATION OF BIOPHARMA COMPANIES

Robotic Process Automation (RPA)

Machine Learning (ML)

MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery) project

AI Lighthouse Projects: Digital Transformation Continues Apace

Evidation, Apple, Eli Lilly and Digital Alzheimer's Biomarkers

Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium

DeepMind Technologies, AI and Protein Folding

AI For Drug Discovery and Accelerating Clinical Trials

Alliance for Artificial Intelligence in Healthcare (AAIH)

MIT's Machine Learning for Pharmaceutical Discovery and Synthesis Consortium

The Challenges Found in Deploying AI
Healx Uses AI to Discover Rare Disease Treatments
Business Strategy Should Include Technology Investment
Empower a Cultural Change: From “Doing Digital” to “Being Digital”
The Implementation of Digital Trials
The Tortoise and the Hare
The Time is Now

CHAPTER 9 LEVERAGING OPEN INNOVATION TO SOLVE DEVELOPMENT CHALLENGES

Collaboration/Partnering
Centers of Innovation
J&J and Pfizer: Global Centers of Innovation
Germany Fosters Biopharma Innovation
Co-location
Crowdsourcing Technical and Scientific Ideas
Other Examples of Open Innovation in Pharma
Otsuka’s Collaboration with the Riken Center for Developmental Biology
AstraZeneca and its Center for Innovation
How Takeda Chose to Move Forward
Internal Crowd Sourcing Through Entrepreneurship Venture Program
External Crowd Sourcing: COCKPI-T
Hybrid model: Innovation Park “Shonan iPark”

CHAPTER 10 THE GLOBAL PHARMA AND BIOTECH MARKET FOR ONCOLOGY

Challenges in Treating Cancer
Clinically Significant Types of Cancers
Lung Cancer
Breast Cancer
Ovarian Cancer
Smarter R&D Leads to More Oncology Drug Approvals
Global Oncology Market by Region and Selected Types
Global Market for Lung Cancer Chemotherapy by Region
Global Market for Breast Cancer Therapy by Region
Global Market for Ovarian Cancer Therapy by Region

CHAPTER 11 THE GLOBAL PHARMA AND BIOTECH MARKET FOR CHRONIC

DISEASES

Chronic Kidney Disease (CKD)
Background to CKD
Renal Disease
Causes of Chronic Kidney Disease
Incidence of End Stage Renal Disease by Country
Prevalence of End Stage Renal Disease by Country
Pharmaceutical Drugs
Global Market for Chronic Kidney Disease Stage 1-5 Drugs
Chronic Respiratory Disease Market
Global Diabetes Therapy Market
Global Chronic Gastrointestinal Market

CHAPTER 12 THE GLOBAL PHARMA AND BIOTECH MARKET FOR CARDIOVASCULAR DISEASE

Global Cardiovascular Drug Market by Region

CHAPTER 13 THE GLOBAL PHARMA AND BIOTECH MARKET FOR NEUROLOGICAL DISEASES

Parkinson's Disease
Overview
Prevalence
Alzheimer's Disease
Overview
Prevalence
Schizophrenia
Overview
Prevalence
Bipolar Disorders
Overview
Prevalence
Depression
Overview
Prevalence
Epileptic Disorders
Overview

Prevalence
Autism Spectrum Disorders
Overview
Prevalence
Global Market for Neurology Therapies by Region

CHAPTER 14 THE GLOBAL PHARMA AND BIOTECH MARKET FOR INFECTIOUS DISEASES

Infectious Diseases
Classification of Infectious Agents
Management of Infectious Diseases
Bacterial Infectious Diseases
Viral Infectious Diseases
HIV/AIDS
Influenza A and Influenza B
Risk Factors
Etiology and Symptoms
Socioeconomic Burden
Global Markets for Infectious Disease Treatments
Global Market for Infectious Disease Treatments by Region

CHAPTER 15 THE GLOBAL PHARMA AND BIOTECH MARKET FOR RARE DISEASES

Legal Definitions of Orphan Diseases
Playing Games with Orphan Drug Approvals?
Genetically Based Tools for Rare Disease R&D

CHAPTER 16 THE CHANGING FUTURE OF BIOPHARMA WORK

Wanted: Digitally Literate Employees Open to Continuous Learning
Acquiring AI Capabilities Through Cloud-Based Enterprise Software with Integrated AI

CHAPTER 17 COMPANY PROFILES

23ANDME
ABBVIE
ALLERGAN PLC

AMGEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BAYER AG
BIOGEN IDEC
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB CO.
CELGENE CORP.
CSL BEHRING
ELI LILLY AND CO.
EXSCIENCIA
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON INC.
MERCK & CO., INC.
NOVARTIS AG
NOVO NORDISK A/S
NUMERATE INC.
PFIZER INC.
ROCHE (F. HOFFMAN-LA ROCHE AG)
SANOFI
VERTEX PHARMACEUTICALS

CHAPTER 18 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Lung, Breast and Ovarian Cancer Therapies, by Region, Through 2024

Summary Table A: Global Chronic Disease Drugs Market, by Region, Through 2024

Summary Table B: Global Cardiovascular Drugs Market, by Region, Through 2024

Summary Table C: Global Market for Neurology Therapies, by Region, Through 2024

Summary Table D: Global Market for Infectious Disease Treatments, by Region, Through 2024

Summary Table E: Global Market for Orphan Drugs, by Region, Through 2024

Table 1: Likely Applications of AI in Pharma and Biotech Companies

Table 2: Selected M&A Deals, 2018-August 2019

Table 3: Selected US Highest-Priced Drugs

Table 4: US FDA Expedited Pathways and Other Attributes, 2017 and 2018

Table 5: US FDA Selected Drug Approvals, 2017 and 2018

Table 6: Selected FDA Orphan Drug Approvals, 2017 and 2018

Table 7: Clinical Trial Challenges and the Role of AI

Table 8: Selected Pharma Companies Utilizing AI

Table 9: Global Cancer Incidence (Both Sexes)

Table 10: Global Markets for Lung, Breast & Ovarian Cancer Therapies, by Region, Through 2024

Table 11: Global Market for Lung Cancer Chemotherapy, by Region, Through 2024

Table 12: Global Market for Breast Cancer Therapy, by Region, Through 2024

Table 13: Global Market for Ovarian Cancer Therapy, by Region, Through 2024

Table 14: Incidence of ESRD, by Country, 2015

Table 15: Prevalence of ESRD, by Country, 2015

Table 16: Global CKD 1-5 Stage Drugs Market, by Region, Through 2024

Table 17: Global Chronic Respiratory Disease Therapies Market, by Region, Through 2024

Table 18: Global Diabetes Therapy Market, by Region, Through 2024

Table 19: Global Chronic Gastrointestinal Therapy Market, by Region, Through 2024

Table 20: Global Cardiovascular Drug Market, by Region, Through 2024

Table 21: AstraZeneca PLC: Cardiovascular Pipeline

Table 22: Amgen Inc.: Cardiovascular Pipeline

Table 23: Sanofi: Cardiovascular Pipeline

Table 24: Novartis AG: Cardiovascular Pipeline

Table 25: Merck and Co., Inc.: Cardiovascular Pipeline

- Table 26: Bristol-Myers Squibb Company: Cardiovascular Pipeline
- Table 27: Global Market for Neurology Therapies, by Region, Through 2024
- Table 28: Global Health Estimates, Leading Causes of Death, Infectious Diseases, by WHO Region, 2015
- Table 29: Prevalence and Incidence of Hepatitis B, 2015
- Table 30: Prevalence and Incidence of Hepatitis C, 2015
- Table 31: Global Prevalence and Incidence of Genital Herpes, 2005-2015
- Table 32: Prevalence of HIV, Adults (15-49 years old), by WHO Region, 2015
- Table 33: New HIV Infections (per 1,000 uninfected population), Adults (15-49 years old), by WHO Region, 2015
- Table 34: New HIV Infections, 2000-2030
- Table 35: Years of Life Lost (YLLs), Pandemic Influenza A H1N1, by WHO Region, 2009
- Table 36: Global Market for Infectious Diseases, by Product Type, Through 2024
- Table 37: Global Market for Infectious Diseases, by Region, Through 2024
- Table 38: Selected Country/Regional Definitions of Orphan Disease
- Table 39: Description of Selected Orphan Diseases
- Table 40: Global Market for Orphan Drugs, by Region, Through 2024
- Table 41: Applications of AI in Pharma and Biotech Companies
- Table 42: Details of Allergan's Late-Stage Pipeline, 2019
- Table 43: Astellas Pharma Inc.: Selected Financials, 2016-2018
- Table 44: Astellas Pharma Inc.: Marketed Products, 2018
- Table 45: AstraZeneca PLC: Selected Financials, 2016-2018
- Table 46: AstraZeneca PLC: Selected Marketed Products, 2018
- Table 47: AstraZeneca PLC: Selected Global Product Sales, 2017 and 2018
- Table 48: Bayer AG: Selected Financials, 2017 and 2018
- Table 49: Biogen: Selected Financials, 2017 and 2018
- Table 50: Boehringer Ingelheim GmbH: Selected Financials, 2017 and 2018
- Table 51: Boehringer Ingelheim GmbH: Top 4 Human Pharmaceutical Product Sales, 2018
- Table 52: Bristol-Myers Squibb Co.: Selected Financials, 2017 and 2018
- Table 53: Bristol-Myers Squibb Co.: Selected Marketed Products, 2018
- Table 54: Celgene Corp.: Selected Financials, 2017 and 2018
- Table 55: Celgene Corp.: Selected Marketed Products, 2018
- Table 56: CSL Behring: Selected Financials, 2017 and 2018
- Table 57: Eli Lilly and Co.: Selected Financials, 2017 and 2018
- Table 58: Eli Lilly and Co.: Selected Products
- Table 59: Gilead Sciences Inc.: Selected Financials, 2017 and 2018
- Table 60: Gilead Science: Selected Products and Indications

Table 61: GlaxoSmithKline PLC: Selected Financials, 2017 and 2018

Table 62: GlaxoSmithKline PLC: Selected Marketed Products

Table 63: Johnson & Johnson Inc.: Selected Financials, 2017 and 2018

Table 64: Johnson & Johnson Inc.: Selected Marketed Products, 2018

Table 65: Merck & Co., Inc.: Selected Financials, 2016-2018

Table 66: Merck & Co., Inc.: Selected Marketed Products, 2018

Table 67: Novartis AG: Net Revenue, 2017 and 2018

Table 68: Novartis AG: Selected Marketed Products, by Indication, 2018

Table 69: Novo Nordisk A/S: Net Revenue, 2017 and 2018

Table 70: Novo Nordisk A/S: Selected Products and Indications, 2018

Table 71: Pfizer Inc.: Net Revenue, 2017 and 2018

Table 72: Pfizer Inc.: Selected Products and Indications, 2018

Table 73: Roche: Net Revenue, 2017 and 2018

Table 74: Roche: Revenues from Top 10 Pharma Products, 2018

Table 75: Sanofi: Net Revenue, 2017 and 2018

Table 76: Sanofi: Selected Products and Indication, 2018

Table 77: Vertex Pharmaceuticals: Net Revenue, 2017 and 2018

Table 78: Acronyms Used in This Report

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Lung, Breast and Ovarian Cancer Therapies, by Region, 2016-2024

Summary Figure A: Global Chronic Disease Drugs Market, by Region, 2016-2024

Summary Figure B: Global Chronic Disease Drugs Market, by Region, 2016-2024

Summary Figure C: Global Chronic Disease Drugs Market, by Region, 2016-2024

Summary Figure D: Global Chronic Disease Drugs Market, by Region, 2016-2024

Summary Figure E: Global Chronic Disease Drugs Market, by Region, 2016-2024

Figure 1: Selected Challenges

Figure 2: Annual Revenues of Leading Pharmaceutical Companies, 2010-2018

Figure 3: Annual Revenues of Leading Biotech Companies, 2010-2018

Figure 4: Selected Pharma Companies' Return on R&D Spend, 2010-2018

Figure 5: Selected Pharma Companies' R&D Spend, 2010-2018

Figure 6: Selected Biotech Companies' R&D Spend, 2010-2018

Figure 7: Pharma/Biotech Drug Development Cycle

Figure 8: Likelihood of Approval from Phase I, by Disease Area

Figure 9: Complexity of Oncology Clinical Trials, 2010-2018

Figure 10: Number of Next-Generation Biotherapeutic Pipeline Products in Late-Stage Pipeline, 2009-2018

Figure 11: Drugs Approval Process, US FDA and EU

Figure 12: China CFDA Drug Regulatory Approval Process

Figure 13: Japan PMDA Drug Regulatory Approval Process

Figure 14: AI for Clinical Trial Design from Methodology to Improved Outcomes

Figure 15: Percentage of US and EU5 Patients Tested for Biomarker, by Cancer Type

Figure 16: Build Digital Capabilities Now

Figure 17: Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1975-2015

Figure 18: Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2012

Figure 19: Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2015

Figure 20: Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries, 1975-2012

Figure 21: Annual Incidence and Mortality Data for Ovarian Cancer in the U.S., 1975-2015

Figure 22: Annual Incidence and Mortality Data for Ovarian Cancer in Five EU Countries, 1975-2012

- Figure 23: Number of New Active Substance Approvals in Oncology, by Indication, 2019
- Figure 24: Global Market for Lung Cancer Chemotherapy, by Region, 2016-2024
- Figure 25: Global Market for Breast Cancer Therapy, by Region, 2016-2024
- Figure 26: Global Market for Ovarian Cancer Therapy, by Region, 2016-2024
- Figure 27: Global Cardiovascular Deaths, by Region, 2015 and 2030 (Forecast)
- Figure 28: Global Health Estimates, Leading Causes of Death, Infectious Diseases, by WHO Region, 2015
- Figure 29: Global Market Share of New HIV Infections, by WHO Region, 2015
- Figure 30: Number of Deaths due to 2009 Pandemic Influenza A H1N1, by WHO Region, August 2009-August 2010
- Figure 31: Global Market for Infectious Diseases, by Product Type, 2016-2024
- Figure 32: Top 10 Pharmaceutical Companies, by Global Orphan Drug Projected Revenues, 2024
- Figure 33: Global Market for Orphan Drugs, by Region, 2016-2024
- Figure 34: AbbVie's Pipeline, at the Time of Proposed Merger with Allergan, June 2019
- Figure 35: Allergan Developments, 2018
- Figure 36: Astellas Pharma Inc.: Revenue Share, by Region, 2018
- Figure 37: Astellas Pharma Inc.: R&D Expenditure, 2017-2019 (forecast)
- Figure 38: AstraZeneca PLC: Revenue Share, by Region, 2018
- Figure 39: AstraZeneca PLC: Revenue Share, by Business Segment, 2018
- Figure 40: AstraZeneca PLC: R&D Expenditure, 2016-2018
- Figure 41: Bayer AG: Regional Sales Share, 2018
- Figure 42: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2018
- Figure 43: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2018
- Figure 44: Boehringer Ingelheim GmbH: R&D Expenditure, 2016-2018
- Figure 45: Bristol-Myers Squibb Co.: Revenue Share, by Region, 2018
- Figure 46: CSL Behring: Sales Share, by Region, FY2018 and FY2019
- Figure 47: Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
- Figure 48: Eli Lilly and Co.: Revenue Share, by Region, 2018
- Figure 49: Gilead Sciences Inc.: Revenue Share, by Region, 2018
- Figure 50: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2018
- Figure 51: GlaxoSmithKline PLC: Revenue Share, by Region, 2018
- Figure 52: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2018
- Figure 53: Johnson & Johnson Inc.: Revenue Share, by Region, 2018
- Figure 54: Merck & Co., Inc.: Revenue Share, by Business Segment, 2018
- Figure 55: Merck & Co., Inc.: Revenue Share, by Region, 2018
- Figure 56: Novartis AG: Revenue Share, by Region, 2018
- Figure 57: Novartis AG: Revenue Share, by Business Segment, 2018
- Figure 58: Novo Nordisk A/S: Revenue Share, by Region, 2018

Figure 59: Novo Nordisk A/S: Revenue Share, by Business Segment, 2018

Figure 60: Pfizer Inc.: Revenue Share, by Region, 2016

Figure 61: Pfizer Inc.: Revenue Share, by Business Segment, 2018

Figure 62: Roche: Revenue Share, by Business Segment, 2018

Figure 63: Roche Pharmaceuticals: Revenue Share, by Region, 2018

Figure 64: Sanofi: Revenue Share, by Country/Region, 2018

Figure 65: Sanofi: Revenue Share, by Business Segment, 2018

I would like to order

Product name: ROI in Pharmaceutical R&D: How to Halt the Decline

Product link: <https://marketpublishers.com/r/RDA9019676C8EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RDA9019676C8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970